Bibliografía
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A: Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians 2017, 67(3):177-193.
2. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. CA: a cancer journal for clinicians 2017, 67(1):7-30.
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer 2018.
4. Butterworth AS, Higgins JP, Pharoah P: Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. European journal of cancer 2006, 42(2):216-227.
5. Brenner H, Kloor M, Pox CP: Colorectal cancer. Lancet 2014, 383(9927):1490-1502.
6. Fakih MG, Padmanabhan A: CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006, 20(6):579-587; discussion 588, 594, 596 passim.
7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105(30):10513-10518.
8. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW: Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6(6):e20769.
9. Ameres SL, Zamore PD: Diversifying microRNA sequence and function. Nature reviews Molecular cell biology 2013, 14(8):475-488.
10. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome research 2009, 19(1):92-105.
11. van Kouwenhove M, Kedde M, Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature reviews Cancer 2011, 11(9):644-656.
12. Lu J, Zhan Y, Feng J, Luo J, Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. International journal of biological sciences 2018, 14(4):390-397.
13. Wang H, Peng R, Wang J, Qin Z, Xue L: Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clinical epigenetics 2018, 10:59.
14. Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. Journal of cellular physiology 2018, 233(8):5574-5588.
15. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
16. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8(8):467-477.
17. Nunez Lopez YO, Victoria B, Golusinski P, Golusinski W, Masternak MM: Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Rep Pract Oncol Radiother 2018, 23(1):6-20.
18. Kolenda T, Guglas K, Rys M, Bogaczynska M, Teresiak A, Blizniak R, Lasinska I, Mackiewicz J, Lamperska KM: Biological role of long non-coding RNA in head and neck cancers. Rep Pract Oncol Radiother 2017, 22(5):378-388.
19. Chen X, Liang H, Zhang J, Zen K, Zhang CY: Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012, 22(3):125-132.
20. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(30):10513-10518.
21. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic oncology 2009, 112(1):55-59.
22. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British journal of haematology 2008, 141(5):672-675.
23. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58(10):1375-1381.
24. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM: Detection and characterization of placental microRNAs in maternal plasma. Clinical chemistry 2008, 54(3):482-490.
25. Luo X, Burwinkel B, Tao S, Brenner H: MicroRNA signatures: novel biomarker for colorectal cancer?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011, 20(7):1272-1286.
26. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J et al: Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. The Lancet Oncology 2013, 14(13):1295-1306.
27. Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M et al: Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis 2016, 37(10):941-950.
28. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 2013, 8(11):e77853.
29. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC cancer 2012, 12:505.
30. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Annals of surgery 2012, 256(3):544-551.
31. Li M, Ma X, Li M, Zhang B, Huang J, Liu L, Wei Y: Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis. Disease markers 2014, 2014:106197.
32. Xie X, Wu W, Liang L, Han S, Chen T, Pan S, Xue M, Li S: Prognostic role of microRNA-210 in various carcinomas: a meta-analysis. International journal of clinical and experimental medicine 2015, 8(9):15283-15289.
33. Fouad H, Sabry D, Morsi H, Shehab H, Abuzaid NF: XRCC1 Gene Polymorphisms and miR-21 Expression in Patients with Colorectal Carcinoma. The Eurasian journal of medicine 2017, 49(2):132-136.
34. Qu A, Du L, Yang Y, Liu H, Li J, Wang L, Liu Y, Dong Z, Zhang X, Jiang X et al: Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PloS one 2014, 9(3):e90952.
35. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72(5-6):397-402.
36. Li M, Zou X, Xia T, Wang T, Liu P, Zhou X, Wang S, Zhu W: A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 2019, 8(16):7006-7017.
37. Yu W, Wang Z, Shen LI, Wei Q: Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis. Mol Clin Oncol. 2016;4(2):237–244.
38. Das V, Kalita J, Pal M: Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed Pharmacother. 2017;87:8–19.